Description
The FDA is seeking a Lonza 4D or equal nucleofection system to support ongoing research involving the transfection of various cell lines. The system must provide highly efficient transfection across a broad range of cell types, particularly human primary cells, and ensure minimal cytotoxicity to preserve cell viability and maintain experimental integrity. The system must also be capable of delivering DNA, RNA, and proteins into cell lines and human primary cells, and must utilize conductive polymer (metal-free) electrodes to eliminate toxic metal ion release during electrical discharge.
• The system must process 2 × 10⁴ to 1 × 10⁷ cells per reaction and shall accommodate low-yield, rare primary patient samples with a minimum operational cell threshold of no more than 2 × 10⁴ cells per single reaction volume.
• The instrument shall achieve post-transfection cell viability of up to 90% under manufacturer-recommended operating conditions.
• The instrument shall utilize a specialized substrate-driving electrical waveform to propel DNA, RNA, and proteins directly across the nuclear membrane of non-dividing cells.
• The system shall contain an onboard software database with factory-preprogrammed, manufacturer-validated pulse protocols specifically calibrated for primary human dendritic cells.